Description:

The trial examines the clinical benefit of adjuvant external beam radiotherapy (RTx) for locally invasive differentiated carcinoma (TNM stages pT4 pN0/1/x M0/x; 5th ed. 1997) of the thyroid gland (DTC). Patients are treated with surgery (thyroidectomy and lymphadenectomy), radioiodine therapy (RIT) to ablate the thyroid remnant tissue, and TSH-suppressive L-thyroxine therapy with or without RTx after documented elimination of cervical I-131 uptake.

Keywords:
Versions (1) ▾
  1. 12/11/13
Uploaded on:

December 11, 2013

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00144079 # Thyroid Carcinoma

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion criteria
18 Years to 69 Years
No Healthy Volunteers
papillary or follicular thyroid carcinoma pT4 pN0/1/x M0/x
completion of primary surgical therapy with R0 (no tumor residues) or R1 (microscopic residues) resection
Karnofsky index > 70 %
freedom from distant metastases at the time of initial radioiodine therapy
informed patient consent
Exclusion criteria
secondary malignancy except basalioma
pregnancy
serious general disease
serious psychiatric disorder
inability to give informed consent
previous RTx
recurrence of previous thyroid cancer
Medical Concepts